Marksans Pharma Limited

As of June 30, 2026, Marksans Pharma Limited carries a market capitalization of 123.63B, placing it among publicly traded companies globally. Its enterprise value stands at 123.63B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Marksans Pharma Limited's next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Marksans Pharma Limited has 453.16M shares outstanding.

As of June 30, 2026, Marksans Pharma Limited trades at a trailing price-to-earnings ratio of 23.91.

As of June 30, 2026, Marksans Pharma Limited trades at an EV/EBITDA multiple of 17.32 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.90 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 20.16 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 123.63B versus a market cap of 123.63B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 20.91M in revenue per employee across its workforce of 1,517.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Marksans Pharma Limited recorded 1.69B in income tax expense. That works out to an effective tax rate of 24.51, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 6.91B, leaving 5.17B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Marksans Pharma Limited's stock has gained approximately 61.00% over the past 52 weeks. The 50-day moving average sits at 322.68, while the 200-day moving average is 236.78.

Over the twelve months ended June 30, 2026, Marksans Pharma Limited generated 31.72B in revenue and converted that into 5.17B in net income, yielding earnings per share of 11.51. EBITDA reached 7.14B, while operating income came in at 6.13B.

Over the twelve months ended June 30, 2026, Marksans Pharma Limited posted a gross margin of 57.16, reflecting its pricing power and cost economics. The operating margin of 19.34 and net profit margin of 16.29 provide insight into operational efficiency.

Marksans Pharma Limited's most recent stock split took place on March 11, 2008 with a 1:10 split ratio.